AAAAAA

   
Results: 1-12 |
Results: 12
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide:A North American brain tumor consortium study. (vol 2, pg 34, 2000)
Authors: Schold, SC Kuhn, JG Chang, SM Bosik, ME Robins, HI Mehta, MP Spence, AM Fulton, D Fink, KL Prados, MD
Citation: Sc. Schold et al., A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide:A North American brain tumor consortium study. (vol 2, pg 34, 2000), NEURO-ONCOL, 3(2), 2001, pp. 123-123
Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas
Authors: Raymond, E Faivre, S Weiss, G McGill, J Davidson, K Izbicka, E Kuhn, JG Allred, C Clark, GM Von Hoff, DD
Citation: E. Raymond et al., Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas, CLIN CANC R, 7(5), 2001, pp. 1171-1180
Fluorouracil and the new oral fluorinated pyrimidines
Authors: Kuhn, JG
Citation: Jg. Kuhn, Fluorouracil and the new oral fluorinated pyrimidines, ANN PHARMAC, 35(2), 2001, pp. 217-227
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks
Authors: Rothenberg, ML Kuhn, JG Schaaf, LJ Rodriguez, GI Eckhardt, SG Villalona-Calero, MA Rinaldi, DA Hammond, LA Hodges, S Sharma, A Elfring, GL Petit, RG Locker, PK Miller, LL von Hoff, DD
Citation: Ml. Rothenberg et al., Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks, ANN ONCOL, 12(11), 2001, pp. 1631-1641
A phase II study of paclitaxel in patients with recurrent malignant gliomausing different doses depending upon the concomitant use of anticonvulsants - A North American Brain Tumor Consortium report
Authors: Chang, SM Kuhn, JG Robins, HI Schold, SC Spence, AM Berger, MS Mehta, MP Pollack, IF Rankin, C Prados, MD
Citation: Sm. Chang et al., A phase II study of paclitaxel in patients with recurrent malignant gliomausing different doses depending upon the concomitant use of anticonvulsants - A North American Brain Tumor Consortium report, CANCER, 91(2), 2001, pp. 417-422
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide:A North American Brain Tumor Consortium study
Authors: Schold, SC Kuhn, JG Chang, SM Bosik, ME Robins, HI Mehta, MP Spence, AM Fulton, D Fink, KL Prados, MD
Citation: Sc. Schold et al., A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide:A North American Brain Tumor Consortium study, NEURO-ONCOL, 2(1), 2000, pp. 34-39
9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus40 T antigen-transgenic mice
Authors: Wu, K Kim, HT Rodriquez, JL Munoz-Medellin, D Mohsin, SK Hilsenbeck, SG Lamph, WW Gottardis, MM Shirley, MA Kuhn, JG Green, JE Brown, PH
Citation: K. Wu et al., 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus40 T antigen-transgenic mice, CLIN CANC R, 6(9), 2000, pp. 3696-3704
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies
Authors: Eckhardt, SG Baker, SD Britten, CD Hidalgo, M Siu, L Hammond, LA Villalona-Calero, MA Felton, S Drengler, R Kuhn, JG Clark, GM Smith, SL MacDonald, JR Smith, C Moczygemba, J Weitman, S Von Hoff, DD Rowinsky, EK
Citation: Sg. Eckhardt et al., Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies, J CL ONCOL, 18(24), 2000, pp. 4086-4097
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors
Authors: Eckhardt, SG Rizzo, J Sweeney, KR Cropp, G Baker, SD Kraynak, MA Kuhn, JG Villalona-Calero, MA Hammond, L Weiss, G Thurman, A Smith, L Drengler, R Eckardt, JR Moczygemba, J Hannah, AL Von Hoff, DD Rowinsky, EK
Citation: Sg. Eckhardt et al., Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors, J CL ONCOL, 17(4), 1999, pp. 1095-1104
Phase II study of phenylacetate in patients with recurrent malignant glioma: A North American brain tumor consortium report
Authors: Chang, SM Kuhn, JG Robins, HI Schold, SC Spence, AM Berger, MS Mehta, MP Bozik, ME Pollack, I Schiff, D Gilbert, M Rankin, C Prados, MD
Citation: Sm. Chang et al., Phase II study of phenylacetate in patients with recurrent malignant glioma: A North American brain tumor consortium report, J CL ONCOL, 17(3), 1999, pp. 984-990
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors
Authors: Drengler, RL Kuhn, JG Schaaf, LJ Rodriguez, GI Villalona-Calero, MA Hammond, LA Stephenson, JA Hodges, S Kraynak, MA Staton, BA Elfring, GL Locker, PK Miller, LL Von Hoff, DD Rothenberg, ML
Citation: Rl. Drengler et al., Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors, J CL ONCOL, 17(2), 1999, pp. 685-696
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
Authors: Rinaldi, DA Kuhn, JG Burris, HA Dorr, FA Rodriguez, G Eckhardt, SG Jones, S Woodworth, JR Baker, S Langley, C Mascorro, D Abrahams, T Von Hoff, DD
Citation: Da. Rinaldi et al., A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation, CANC CHEMOT, 44(5), 1999, pp. 372-380
Risultati: 1-12 |